At the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, Dr. Henry Kuerer presented results from a study looking at whether some women diagnosed with early-stage triple-negative breast cancer or early-stage HER2-positive breast cancer could skip surgery if they had a pathologic complete response to chemotherapy before surgery.

Listen to the podcast to hear Dr. Kuerer explain:

what a pathologic complete response is

why no women diagnosed with hormone receptor-positive disease were in the study

the results of the study

what the next steps are for this research